EUVIMEDEUVIMED entdecken
Crossref

An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases

Michael J McPherson iD, Adrian D Hobson iD, Axel Hernandez, Christopher C Marvin iD, Wendy Waegell, Christian Goess iD, Jason Z Oh iD, Dan Shi iD, Martin E Hayes iD, Lu Wang iD, Lu Wang iD, Diana Schmidt iD und 24 weitere

Science Translational Medicine · 20.03.2024 · 16 (739)

DOI: 10.1126/scitranslmed.add8936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 20.03.2024. Verfasst von Michael J McPherson und 35 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: Arthritis, Experimental, Immunoconjugates, Antibodies, Steroids. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoids (GCs) are efficacious drugs used for treating many inflammatory diseases, but the dose and duration of administration are limited because of severe side effects. We therefore sought to identify an approach to selectively target GCs to inflamed tissue. Previous work identified that anti–tumor necrosis factor (TNF) antibodies that bind to transmembrane TNF undergo internalization; therefore, an anti-TNF antibody-drug conjugate (ADC) would be mechanistically similar, where lysosomal catabolism could release a GC receptor modulator (GRM) payload to dampen immune cell activity. Consequently, we have generated an anti–TNF-GRM ADC with the aim of inhibiting pro-inflammatory cytokine production from stimulated human immune cells. In an acute mouse model of contact hypersensitivity, a murine surrogate anti–TNF-GRM ADC inhibited inflammatory responses with minimal effect on systemic GC biomarkers. In addition, in a mouse model of collagen-induced arthritis, single-dose administration of the ADC, delivered at disease onset, was able to completely inhibit arthritis for greater than 30 days, whereas an anti-TNF monoclonal antibody only partially inhibited disease. ADC treatment at the peak of disease was also able to attenuate the arthritic phenotype. Clinical data for a human anti–TNF-GRM ADC (ABBV-3373) from a single ascending dose phase 1 study in healthy volunteers demonstrated antibody-like pharmacokinetic profiles and a lack of impact on serum cortisol concentrations at predicted therapeutic doses. These data suggest that an anti–TNF-GRM ADC may provide improved efficacy beyond anti-TNF alone in immune mediated diseases while minimizing systemic side effects associated with standard GC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, ExperimentalImmunoconjugatesAntibodiesSteroidsHumansAnimalsMicePharmaceutical PreparationsReceptors, GlucocorticoidTumor Necrosis Factor InhibitorsGlucocorticoidsTumor Necrosis Factor-alphaDisease Models, Animal

Substanzen

ABBV-3373Pharmaceutical PreparationsReceptors, GlucocorticoidTumor Necrosis Factor InhibitorsGlucocorticoidsTumor Necrosis Factor-alphaImmunoconjugatesAntibodiesSteroids

Autor:innen und Institutionen

  • AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
  • AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, USA.
  • AbbVie Bay Area, 1000 Gateway Boulevard, South San Francisco, CA 94080, USA.

ORCID-Profile: Michael J McPherson, Adrian D Hobson, Christopher C Marvin, Christian Goess, Jason Z Oh, Dan Shi, Martin E Hayes, Lu Wang, Lu Wang, Diana Schmidt, Zhi Wang, Kimberley McCarthy, Ying Jia, Ce Wang, Bit Na Kang, Shaughn Bryant, Suzanne Mathieu, Melanie Ruzek, Ronilda R D'Cunha, Yinuo Pang, Nathan J Brown, Jianwen Xu, Candace Graff, Yu Tian, Wei Qiu, Pingping Zheng, Yingtao Bi, Robert Stoffel

Zitieren

APA

McPherson, M. J., Hobson, A. D., Hernandez, A., Marvin, C. C., Waegell, W., Goess, C., Oh, J. Z., Shi, D., Hayes, M. E., Wang, L., Wang, L., Schmidt, D., Wang, Z., Pitney, V., McCarthy, K., Jia, Y., Wang, C., Kang, B. N., Bryant, S., …, & Stoffel, R. (2024). An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases. Science Translational Medicine, 16(739). https://doi.org/10.1126/scitranslmed.add8936

Vancouver

McPherson MJ, Hobson AD, Hernandez A, Marvin CC, Waegell W, Goess C, et al. An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases. Science Translational Medicine. 2024;16(739). doi:10.1126/scitranslmed.add8936

BibTeX
@article{McPherson2024,
  author = {McPherson, Michael J and Hobson, Adrian D and Hernandez, Axel and Marvin, Christopher C and Waegell, Wendy and Goess, Christian and Oh, Jason Z and Shi, Dan and Hayes, Martin E and Wang, Lu and Wang, Lu and Schmidt, Diana and Wang, Zhi and Pitney, Victoria and McCarthy, Kimberley and Jia, Ying and Wang, Ce and Kang, Bit Na and Bryant, Shaughn and Mathieu, Suzanne and Ruzek, Melanie and Parmentier, Julie and D'Cunha, Ronilda R and Pang, Yinuo and Phillips, Lucy and Brown, Nathan J and Xu, Jianwen and Graff, Candace and Tian, Yu and Longenecker, Kenton L and Qiu, Wei and Zhu, Haizhong and Liu, Wei and Zheng, Pingping and Bi, Yingtao and Stoffel, Robert},
  title = {An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {739},
  doi = {10.1126/scitranslmed.add8936}
}
Kostenlos starten →